Department of Infectious Diseases, Infection Control & Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Future Microbiol. 2020 Apr;15:389-400. doi: 10.2217/fmb-2019-0288. Epub 2020 Mar 13.
Brincidofovir (BCV) is a lipid conjugate of cidofovir with good oral bioavailability, enabling optimal intracellular levels of the active drug. Lower rates of nephrotoxicity and myelotoxicity make it a favorable alternative. Despite a greater safety profile among pediatric hematopoietic cell transplant recipients, the oral formulation has been associated with increased gastrointestinal toxicity in adult hematopoietic cell transplant recipients. Oral BCV continues to be developed as a countermeasure against smallpox, while a potentially safer intravenous preparation has been out licensed to another company. BCV has demonstrated great potency against double-stranded DNA viruses, especially adenovirus. Because of its importance for immunocompromised patients, this review aims to evaluate BCV's clinical and safety profile to support its continued development.
布昔洛韦（BCV）是一种具有良好口服生物利用度的更昔洛韦脂质复合物，能够使活性药物在细胞内达到最佳水平。较低的肾毒性和骨髓抑制毒性使其成为一种更理想的替代药物。尽管在儿科造血细胞移植受者中具有更好的安全性特征，但口服制剂与成人造血细胞移植受者中增加的胃肠道毒性有关。口服布昔洛韦仍在被开发作为对抗天花的对策，而一种潜在更安全的静脉制剂已被授权给另一家公司。BCV 对双链 DNA 病毒（尤其是腺病毒）具有很强的活性。由于其对免疫功能低下患者的重要性，本综述旨在评估 BCV 的临床和安全性特征，以支持其持续开发。
